Shares of Valeant Pharmaceuticals Intl Inc VRX were trading lower by nearly 2 percent early morning after the company released its delayed 10-k filing which includes its first quarter results.
Valeant reported it lost $1.12 per share in the first quarter on revenue of $2.76 billion. Wall Street analysts were expecting the company to earn $1.38 per share on revenue of $2.72 billion.
Valeant pledged to release its 10-k results on or before Friday to avoid being considered in default by its lenders.
The financial statements in the regulatory filing restate results for the fiscal year ending December 31, 2014, the three months ending December 31, 2014, the three months ending March 31, 2015, the six-month period ending June 30, 2015 and the nine months ending September 30, 2015.
Valeant also disclosed in its filing it has received two probes by districts in Massachusetts and the Southern District of New York, which relate to its patient assistance program and its accounting treatment of sales to specialty pharmacies.
The company also added it faces an investigation probe by the state of North Carolina related to the production, marketing, distribution, sale and pricing of some of its drugs.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
